OncoHisto–Development of efficient and selective treatment for glioblastoma patients
| Reference number | |
| Coordinator | Oncopeptides AB |
| Funding from Vinnova | SEK 801 226 |
| Project duration | November 2024 - October 2025 |
| Status | Ongoing |
| Venture | Utlysning Infrastruktur for the development of accurate drug treatment |
| Call | Use infrastructures to develop precision medicine |
Purpose and goal
The aim of the HistoCore project is to understand the precision and selectivity of novel drug candidates developed by Oncopeptides for treatment of glioblastoma (GBM). In the OncoHisto project, the core facility Histocore at Karolinska Institutet will support Oncopeptides to evaluate the drug candidates by use of advanced immunohistochemistry techniques and analysis of complex staining patterns using innovative AI tools.
Expected effects and result
The heterogeneous nature of glioblastoma tumors contributes to the difficulty in improving survival for this patient group. In vitro data indicate that certain glioblastoma cells are highly resistant to treatment and thereby contribute to disease progression. Within the OncoHisto project, both selectivity and precision will be studied in more advanced systems that better mimic the complexity of glioblastoma patients.
Planned approach and implementation
Tissues from glioblastoma studies will be provided from Oncopeptides to HistoCore. HistoCore will set up immunohistochemical methods for the analysis of the effect of drug candidates, developed by Oncopeptides. HistoCore will also develop innovative AI methods for the analysis of stained tissue.